Drug-resistant human immunodefiency virus

Clinical Microbiology and Infection

Volumn 15, Issue SUPPL. 1, 2009, Pages 69-73

  Kozal, Michael J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; HIV drug resistance; HIV genotyping

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

DRUG APPROVAL; DRUG CLASSIFICATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; EPIDEMIOLOGICAL DATA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 59649092052     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.02687.x     Document Type: Review

References (23)

1. DHHS HIV treatment guidelines 2007; US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Washington, DC: US Government Printing OfficeH 2007. Available at: http://www.aidsinfo.gov.
2. Clavel F. HIV drug resistance. N Engl J Med 2004; 350: 1023-1032.
3. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2007; 15: 119-122.
4. Hogg R, Bangsberg D, Lima VD et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3: 1570-1577.
5. MacArthur RD, Novak RM, Peng G et al. Long-term clinical and immunologic outcomes are similar in HIV-infected persons randomized to NNRTI versus PI versus NNRTI+PI-based antiretroviral regimens as initial therapy: results of the CPCRA 058 FIRST Study. Lancet 2006; 368: 2125-2135.
6. Zaccarelli M, Tozzi V, Lorenzini P et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005; 19: 1081-1089.
7. Kozal MJ, Huppler Hullsiek K, MacArthur RD et al. The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral naïve participants started on three different antiretroviral therapy strategies. HIV Clin Trials 2007; 6: 357-370.
8. Kozal MJ, Amico KR, Chiarella J et al. Antiretroviral resistance and high-risk transmission behavior among HIV+ patients in clinical care. AIDS 2004; 18: 2185-2189.
9. Coffin JM. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483-489.
10. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-1586.
11. Daar ES, Richman DD. Confronting the emergence of drug-resistant HIV type 1: Impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses 2005; 21: 343-357.
12. Kozal MJ, Amico KR, Chiarella J et al. HIV drug resistance and HIV transmission risk behaviors in injection drug users. J Acquir Immune Defic Syndr 2005; 40: 106-109.
13. Kozal MJ, Amico KR, Chiarella J et al. A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care. MedGenMed 2006; 8: 72.
14. Richman DD, Morton SC, Wrin T et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18: 1393-1401.
15. von Wyl V, Yerly S, Boni J et al. The proportion of individuals without further treatment options has stabilized at low levels in the Swiss HIV cohort study. CROI 2008, Boston MA, 3-6 February 2008, Abstract 896.
16. Lima V, Hudson E, Wynhoven B et al. Drastically declining incidence of HIV drug resistance: The end of the beginning? CROI 2008, Boston MA, 3-6 February 2008, Abstract 895.
17. Vella S, Palmisano L. The global status of resistance to antiretroviral drugs. Clin Infect Dis 2005; 41 (suppl 4): S239-S246.
18. World Health Organization HIV Department. Prioritizing second-line antiretroviral drugs for adults and adolescents: A public health approach. A report of a WHO working group meeting. Geneva: World Health Organization HIV Department, 2007; 1-43.
19. Wensing AM, van de Vijver DA, Angarano G et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192: 958-966.
20. Weinstock HS, Zaidi I, Heneine W et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189: 2174-2180.
21. Bennett DE. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Current Opin Infect Dis 2006; 19: 607-614.
22. Johnson J, Li JF, Wei X et al. Low-frequency mutations substantially increase the prevalence of transmitted drug resistance and greatly strengthen the relationship between resistance mutations and virologic failure. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, 25-28 February 2007, Abstract 639.
23. Simen BB, Simons JF, Huppler Hullsiek K, et al. Low Abundance Drug Resistant Viral Variants in Chronically HIV-infected Antiretroviral Naïve Patients Significantly Impact Treatment Outcomes. Journal of Infectious Diseases. 2009; 199: 1-9.